Literature DB >> 11273739

Murine monoclonal antibodies to PorA of Neisseria meningitidis show reduced protective activity in vivo against B:15:P1.7,16 subtype variants in an infant rat infection model.

M Toropainen1, L Saarinen, P van der Ley, B Kuipers, H Käyhty.   

Abstract

The major outer membrane protein PorA of Neisseria meningitidis is the target for bactericidal serosubtyping antibodies and is currently considered as a potential vaccine candidate against group B meningococcal disease. Although the minor antigenic variability of the PorA has been increasingly recognized and described, its implication for vaccine design remains unclear. In this study, the protective activity of murine monoclonal PorA specific antibodies against four isogenic meningococcal P1.7,16 target strains, the prototype P1.7,16a and three loop 4 point mutation variants (designated P1.7,16b to d) constructed from reference strain H44/76 (B:15:P1.7,16a), was evaluated in the infant rat infection model. All monoclonal antibodies had been obtained by immunization of mice with outer membrane protein preparations from meningococcal serosubtype P1.7,16 reference strain H44/76. A challenge dose of 10(5)cfu/pup was given i.p. 1-2 h after the i.p. injection of 1:100 diluted antibodies, and the development of bacteremia was assessed by culturing blood samples taken 6 h after challenge. MN14C11.6, a reference monoclonal antibody for serosubtype P1.7 epitope located in predicted loop 1 (VR1) identical in all the variants, was equally protective against all loop 4 variants. The three P1.16 specific monoclonal antibodies tested (MN5C11G, MN12H2 and 62D12-8) all completely protected animals against the prototype P1.7,16a, variably against the P1.7,16b and P1.7,16c, but not against the P1.7,16d variant. Our findings therefore suggest that certain subtype variants may escape protection in vivo conferred by PorA specific antibodies. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11273739     DOI: 10.1006/mpat.2000.0419

Source DB:  PubMed          Journal:  Microb Pathog        ISSN: 0882-4010            Impact factor:   3.738


  10 in total

1.  Specific ligand binding attributable to individual epitopes of gonococcal transferrin binding protein A.

Authors:  Heather P Masri; Cynthia Nau Cornelissen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

2.  Protection by meningococcal outer membrane protein PorA-specific antibodies and a serogroup B capsular polysaccharide-specific antibody in complement-sufficient and C6-deficient infant rats.

Authors:  Maija Toropainen; Leena Saarinen; Gestur Vidarsson; Helena Käyhty
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

3.  Inhibition of the alternative pathway of nonhuman infant complement by porin B2 contributes to virulence of Neisseria meningitidis in the infant rat model.

Authors:  Lisa A Lewis; David M Vu; Dan M Granoff; Sanjay Ram
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

4.  Protection by natural human immunoglobulin M antibody to meningococcal serogroup B capsular polysaccharide in the infant rat protection assay is independent of complement-mediated bacterial lysis.

Authors:  Maija Toropainen; Leena Saarinen; Elisabeth Wedege; Karin Bolstad; Terje E Michaelsen; Audun Aase; Helena Käyhty
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

5.  Genotypic and phenotypic characterization of carriage and invasive disease isolates of Neisseria meningitidis in Finland.

Authors:  Ulla Jounio; Annika Saukkoriipi; Holly B Bratcher; Aini Bloigu; Raija Juvonen; Sylvi Silvennoinen-Kassinen; Ari Peitso; Terttu Harju; Olli Vainio; Markku Kuusi; Martin C J Maiden; Maija Leinonen; Helena Käyhty; Maija Toropainen
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

6.  Functional activity of antibodies against the recombinant OpaJ protein from Neisseria meningitidis.

Authors:  M I de Jonge; G Vidarsson; H H van Dijken; P Hoogerhout; L van Alphen; J Dankert; P van der Ley
Journal:  Infect Immun       Date:  2003-05       Impact factor: 3.441

7.  Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera.

Authors:  Dan M Granoff; Jo Anne Welsch; Sanjay Ram
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 8.  Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease.

Authors:  Dan M Granoff
Journal:  Vaccine       Date:  2009-05-23       Impact factor: 3.641

9.  Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity.

Authors:  Joyce S Plested; Jo Anne Welsch; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2009-04-01

10.  Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: influence on endotoxic and adjuvant activity.

Authors:  Jesús Arenas; Harry van Dijken; Betsy Kuipers; Hendrik Jan Hamstra; Jan Tommassen; Peter van der Ley
Journal:  Clin Vaccine Immunol       Date:  2010-01-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.